Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M., Adams, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908492 · Cited by 3,034 · cited 1×
“In the RV144 Thai phase III trial,(9) a reduced risk of infection (31%) in vaccinated individuals did not correlate with serum neutralizing activities but with high concentrations of anti-V1-V2 NoNAbs,(10) providing additional support for a possible contribution of NoNAb functions to protection.(9) Neutralization is t…”
BackgroundImmune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Haynes, B. F., Gilbert, P. B., McElrath, M. J., Zolla-Pazner, S., Tomaras, G. D., Alam, S. M., Evans, D. T., Montefiori, D. C., Karnasuta, C., Sutthent, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113425 · Cited by 1,808
Self-citationFc receptor but not complement binding is important in antibody protection against HIV
Hessell, A. J., Hangartner, L., Hunter, M., Havenith, C. E. G., Beurskens, F. J., Bakker, J. M., Lanigan, C. M. S., Landucci, G., Forthal, D. N., Parren, P. W. H. I., et al. (2007) · Nature · doi:10.1038/nature06106 · Cited by 901 · cited 3×
“Involvement of Fc-mediated inhibition following human mAb transfer has been previously demonstrated by b12mutant LALA.3 Indeed, IgG1 from human or macaque origin showed identical FcgR interaction and ADCC effector function profile in both human and NHP cells.32 We further demonstrated that the Fc-mediated inhibitory a…”
BackgroundParren, P. W. H. I., Marx, P. A., Hessell, A. J., Luckay, A., Harouse, J., Cheng-Mayer, C., Moore, J. P., & Burton, D. R. (2001) · Journal of Virology · doi:10.1128/jvi.75.17.8340-8347.2001 · Cited by 662
Hessell, A. J., Poignard, P., Hunter, M., Hangartner, L., Tehrani, D. M., Bleeker, W. K., Parren, P. W. H. I., Marx, P. A., & Burton, D. R. (2009) · Nature Medicine · doi:10.1038/nm.1974 · Cited by 546 · cited 1×
“Furthermore, subsequent passive infusion studies demonstrated that the protective efficacy of this NAb against vaginal SHIV challenge was significantly reduced by the LALA mutation that impaired its binding to Fcg receptors (FcgRs).(3,12) Mechanisms by which the Fc region of immunoglobulin G (IgG) participates in this…”
BackgroundBUCHACHER, A., PREDL, R., STRUTZENBERGER, K., STEINFELLNER, W., TRKOLA, A., PURTSCHER, M., GRUBER, G., TAUER, C., STEINDL, F., JUNGBAUER, A., et al. (1994) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1994.10.359 · Cited by 529 · cited 1×
“Shortly, nAbs 2G12, 2F5, and 4E10were expressed in Chinese hamster ovary cells as human IgG1 (k).(29,44) NoNAbs anti-PID 246-D IgG1 (k) and 4B3 (IgG1 (l) were expressed in hybridoma cells.”
BackgroundHessell, A. J., Rakasz, E. G., Poignard, P., Hangartner, L., Landucci, G., Forthal, D. N., Koff, W. C., Watkins, D. I., & Burton, D. R. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000433 · Cited by 497
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys
Barouch, D. H., Liu, J., Li, H., Maxfield, L. F., Abbink, P., Lynch, D. M., Iampietro, M. J., SanMiguel, A., Seaman, M. S., Ferrari, G., et al. (2012) · Nature · doi:10.1038/nature10766 · Cited by 465 · cited 1×
“Mechanisms by which the Fc region of immunoglobulin G (IgG) participates in this protection are not fully understood.(6,8,13,14) Antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated virus replication inhibition require binding to FcgRs expressed by killer cells and lead to the killing o…”
BackgroundMoldt, B., Rakasz, E. G., Schultz, N., Chan-Hui, P.-Y., Swiderek, K., Weisgrau, K. L., Piaskowski, S. M., Bergman, Z., Watkins, D. I., Poignard, P., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214785109 · Cited by 463 · cited 1×
“The observed protectionwould likely be further improved with combinations of newer generation of very potent, broadly neutralizingAbs, where their increased potency might allow for dose-sparing effects.(36) Interestingly, although not preventing infection, a modest decrease in viral load was observed in several of the…”
BackgroundNature of Nonfunctional Envelope Proteins on the Surface of Human Immunodeficiency Virus Type 1
Moore, P. L., Crooks, E. T., Porter, L., Zhu, P., Cayanan, C. S., Grise, H., Corcoran, P., Zwick, M. B., Franti, M., Morris, L., et al. (2006) · Journal of Virology · doi:10.1128/jvi.80.5.2515-2528.2006 · Cited by 343 · cited 2×
“displays a diversity of envelope structures on its membrane in addition to functional trimers that include noncleaved trimers, dimers, monomers, as well as gp41 stumps that have shed gp120.(11) Abs against these structures are more easily induced but are nonneutralizing.”
BackgroundDistinct Pathogenic Sequela in Rhesus Macaques Infected with CCR5 or CXCR4 Utilizing SHIVs
Harouse, J. M., Gettie, A., Tan, R. C. H., Blanchard, J., & Cheng-Mayer, C. (1999) · Science · doi:10.1126/science.284.5415.816 · Cited by 320 · cited 1×
“This virus expressed the R5-clade B envelope of HIV-1SF162 and was produced on macaque PBMCs after three in vivo passages in macaques.(30,31) Efficient protection from acquisition of SHIV infection was obtained with the combination of NAbs only and with equal efficacy at 1 h (66%, w(2) P1⁄4 0.”
BackgroundHezareh, M., Hessell, A. J., Jensen, R. C., van de Winkel, J. G. J., & Parren, P. W. H. I. (2001) · Journal of Virology · doi:10.1128/jvi.75.24.12161-12168.2001 · Cited by 294
Gómez-Román, V. R., Patterson, L. J., Venzon, D., Liewehr, D., Aldrich, K., Florese, R., & Robert-Guroff, M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.4.2185 · Cited by 276 · cited 1×
“However, other Ab properties might also play a role in antibody-mediated protection in addition to neutralization of infectious viral particles.(6,7) It is now widely accepted that nonneutralizing antibodies (NoNAbs) as well as NAbs display inhibitory activities against HIV-1 replication in vitro based on different me…”
BackgroundBurton, D. R., Hessell, A. J., Keele, B. F., Klasse, P. J., Ketas, T. A., Moldt, B., Dunlop, D. C., Poignard, P., Doyle, L. A., Cavacini, L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103012108 · Cited by 255 · cited 7×
“The demonstration that vaginal application of the monoclonal Ab (mAb) b12 (directed against the CD4 binding site of gp120) confers protection in a NHP challengemodel provided an important proof of concept for the potential of a NAb-based microbicide.(6) However, b12 alone leads to insufficient breath of protection aga…”
BackgroundMethodInfluentialLi, Z., Palaniyandi, S., Zeng, R., Tuo, W., Roopenian, D. C., & Zhu, X. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012861108 · Cited by 224
Fc receptor-mediated antiviral antibodies
Forthal, D. N., & Moog, C. (2009) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32832f0a89 · Cited by 181 · cited 5×
“Furthermore, subsequent passive infusion studies demonstrated that the protective efficacy of this NAb against vaginal SHIV challenge was significantly reduced by the LALA mutation that impaired its binding to Fcg receptors (FcgRs).3,12 Mechanisms by which the Fc region of immunoglobulin G (IgG) participates in this p…”
BackgroundSelf-citationHoll, V., Peressin, M., Decoville, T., Schmidt, S., Zolla‐Pazner, S., Aubertin, A.-M., & Moog, C. (2006) · Journal of Virology · doi:10.1128/jvi.02625-05 · Cited by 166 · cited 5×
“Neutralization assays using PBMCs as target cells were performed in parallel to Fc-mediated inhibitory assays on MDMs as previously described by Holl et al.(16,17) Briefly, unless otherwise stated, PBMCs and MDMs were purified, cultured, and differentiated from human HIV-1-seronegative blood donors.”
BackgroundMethodSelf-citationInternational Network for Comparison of HIV Neutralization Assays: The NeutNet Report II
Heyndríckx, L., Heath, A., Sheik-Khalil, E., Alcamí, J., Bongertz, V., Jansson, M., Malnati, M., Montefiori, D. C., Moog, C., Morris, L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036438 · Cited by 146
Self-citationMoldt, B., Shibata‐Koyama, M., Rakasz, E. G., Schultz, N., Kanda, Y., Dunlop, D. C., Finstad, S. L., Jin, C., Landucci, G., Alpert, M. D., et al. (2012) · Journal of Virology · doi:10.1128/jvi.00491-12 · Cited by 136 · cited 1×
“This may explain the lack of correlation between in vitro tested antiviral activity(33) and protection in vivo.(34) Combinations of either NAbs (2G12þ 2F5þ 4E10) or NoNAbs (246-Dþ 4B3) were applied locally before the vaginal challenge with a single high dose of SHIVSF162P3.”
MethodSmalls-Mantey, A., Doria‐Rose, N. A., Klein, R. M., Patamawenu, A. A., Migueles, S. A., Ko, S., Hallahan, C. W., Wong, H. C., Liu, B., You, L., et al. (2012) · Journal of Virology · doi:10.1128/jvi.00287-12 · Cited by 128 · cited 2×
“Under these conditions, the activity of mAbswas higher than those described in the recently published study by Smalls-Mantey et al.20 and could therefore be classified as having significant ADCC activity.”
ResultWarncke, M., Calzascia, T., Coulot, M., Balke, N., Touil, R., Kolbinger, F., & Heusser, C. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200090 · Cited by 102 · cited 1×
“Indeed, IgG1 from human or macaque origin showed identical FcgR interaction and ADCC effector function profile in both human and NHP cells.(32) We further demonstrated that the Fc-mediated inhibitory activity of human IgG1 was conserved on macaque MDMs, suggesting that local vaginal application of 246-Dþ 4B3 NoNAbs fo…”
BackgroundSibéril, S., de Romeuf, C., Bihoreau, N., Fernandez, N., Meterreau, J.-L., Regenman, A., Nony, E., Gaucher, C., Glacet, A., Jorieux, S., et al. (2005) · Clinical Immunology · doi:10.1016/j.clim.2005.10.008 · Cited by 99
Self-citationPerez, L. G., Costa, M. R., Todd, C. A., Haynes, B. F., & Montefiori, D. C. (2009) · Journal of Virology · doi:10.1128/jvi.00656-09 · Cited by 91
Holl, V., Hemmerter, S., Burrer, R., Schmidt, S., Bohbot, A., Aubertin, A.-M., & Moog, C. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.10.6274 · Cited by 81
Self-citationHoll, V., Peressin, M., Schmidt, S., Decoville, T., Zolla‐Pazner, S., Aubertin, A.-M., & Moog, C. (2006) · Blood · doi:10.1182/blood-2005-08-3490 · Cited by 74 · cited 1×
“Interestingly, despite having no neutralizing activity on primary CD4þ T lymphocytes, some NoNAbs demonstrated broad and potent ADCC and Fc-mediated inhibitory activities (Figure 4) in agreement with previous reports.(13,18) NoNAbs 246-D and 4B3 mAbs displayed different inhibitory functions that contributed to a high…”
ResultSelf-citationMoldt, B., Schultz, N., Dunlop, D. C., Alpert, M. D., Harvey, J. D., Evans, D. T., Poignard, P., Hessell, A. J., & Burton, D. R. (2011) · Journal of Virology · doi:10.1128/jvi.05541-11 · Cited by 65
Fcγ Receptor-like Activity of Hepatitis C Virus Core Protein
Maillard, P., Lavergne, J.-P., Sibéril, S., Faure, G., Roohvand, F., Pêtres, S., Teillaud, J., & Budkowska, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311470200 · Cited by 53
Self-citationBurrer, R., Haessig, S., Aubertin, A.-M., & Moog, C. (2005) · Virology · doi:10.1016/j.virol.2004.12.034 · Cited by 45 · cited 2×
“The assay measures the concentration of whole native virus particles captured bymAbs coated onto 96-well plates (Maxisorp, Nunc, Rocksilde, Denmark) as previously described.(21,45) Briefly, HIV infectious particles were incubated in mAb-coated ELISA plates for 1 h.”
BackgroundMethodSelf-citationVerrier, B., Grand, R. L., Ataman‐Önal, Y., Terrat, C., Guillon, C., Durand, P.-Y., Hurtrel, B., Aubertin, A.-M., Sutter, G., Erfle, V., et al. (2002) · DNA and Cell Biology · doi:10.1089/104454902760330183 · Cited by 43
Dereuddre‐Bosquet, N., Morellato, L., Brouwers, J., Augustijns, P., Bouchemal, K., Ponchel, G., Ramos, O. H. P., Herrera, C., Stefanidou, M., Shattock, R. J., et al. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1003071 · Cited by 37 · cited 1×
“Confirming this hypothesis, we recently reported that a small peptide competing with CD4 through binding to gp120 CD4 also efficiently prevent SHIV mucosal transmission.(35) The observed protection would likely be further improved with combinations of newer generation of very potent, broadly neutralizing Abs, where th…”
BackgroundSelf-citationBourry, O., Brochard, P., Souquière, S., Makuwa, M., Calvo, J., Dereuddre‐Bosquet, N., Martinon, F., Bénech, H., Kazanji, M., & Grand, R. L. (2009) · AIDS · doi:10.1097/qad.0b013e328321302d · Cited by 34 · cited 2×
“Intravaginal challenge was carried out with B10 AID50 (50% animal infectious dose) of SHIVSF162P3,(31) inoculated in 50% human seminal plasma.(47) Plasma viremia was evaluated as previously described using quantitative reverse transcriptase–PCR for the measurement of viral RNA copy numbers.”
MethodSelf-citationHuber, M., von Wyl, V., Ammann, C. G., Kuster, H., Stiegler, G. M., Katinger, H. W. D., Weber, R. K., Fischer, M., Stoiber, H., Günthard, H. F., et al. (2008) · Journal of Virology · doi:10.1128/jvi.02569-07 · Cited by 30
Peressin, M., Holl, V., Schmidt, S., Decoville, T., Mirisky, D., Lederle, A., Delaporte, M., Xu, K., Aubertin, A., & Moog, C. (2010) · Journal of Virology · doi:10.1128/jvi.01619-10 · Cited by 26 · cited 2×
“Interestingly, despite having no neutralizing activity on primary CD4þ T lymphocytes, some NoNAbs demonstrated broad and potent ADCC and Fc-mediated inhibitory activities (Figure 4) in agreement with previous reports.(13,18) NoNAbs 246-D and 4B3 mAbs displayed different inhibitory functions that contributed to a high…”
BackgroundResultSelf-citationNyambi, P. N., Burda, S. T., Bastiani, L., & Williams, C. A. U. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(01)00384-2 · Cited by 17 · cited 1×
“The assay measures the concentration of whole native virus particles captured bymAbs coated onto 96-well plates (Maxisorp, Nunc, Rocksilde, Denmark) as previously described.(21,45) Briefly, HIV infectious particles were incubated in mAb-coated ELISA plates for 1 h.”
Method
Cited by
Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses
Chen, Y., Zhao, X., Zhou, H., Zhu, H., Jiang, S., & Wang, P. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00784-3 · Cited by 383
Nonneutralizing Functional Antibodies: a New “Old” Paradigm for HIV Vaccines
Excler, J.-L., Ake, J., Robb, M. L., Kim, J. H., & Plotkin, S. A. (2014) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00230-14 · Cited by 114
Amadori, C., van der Velden, Y. U., Bonnard, D., Orlov, I., van Bel, N., Le Rouzic, E., Miralles, L., Brias, J., Chevreuil, F., Spehner, D., et al. (2017) · Retrovirology · doi:10.1186/s12977-017-0373-2 · Cited by 22
Self-citation
Metadata
- Authors
- Moog, C., Dereuddre-Bosquet, N., Teillaud, J.-L., Biedma, M. E., Holl, V, Van Ham, G., Heyndrickx, L., Van Dorsselaer, A., Katinger, D., Vcelar, B., Zolla-Pazner, S., Mangeot, I., Kelly, C., Shattock, R. J., & Le Grand, R.
- Venue
- Mucosal Immunology
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 7
- Issue
- 1
- Pages
- 46-56
- ISSN
- 1933-0219 (ISSN-L)
- OpenAlex
- W1993675648
- Cited by
- 158
- References
- 35
- FWCI
- 9.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.